A Retrospective Study to Assess the Effect of Immune Checkpoint Inhibition (ICI) in Patients with Stage-IV Non-Small Cell Lung Cancer (NSCLC)
Latest Information Update: 24 Sep 2019
At a glance
- Drugs Atezolizumab (Primary) ; Ipilimumab (Primary) ; Nivolumab (Primary) ; Pembrolizumab (Primary) ; Antineoplastics; Immunotherapies
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
Most Recent Events
- 24 Sep 2019 New trial record
- 10 Sep 2019 Results (n=140) assessing the effect of metastatic location on survival in stage IV non-small cell lung cancer treated with immunotherapy, were presented at the 20th World Conference on Lung Cancer.